PDS Biotechnology Corp Files 8-K
Ticker: PDSB · Form: 8-K · Filed: May 10, 2024 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | May 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
PDS Biotech filed an 8-K for 'Other Events' and financials - no specifics yet, but keep an eye out.
AI Summary
On May 9, 2024, PDS Biotechnology Corporation filed an 8-K report to disclose information regarding "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific new events or financial figures but serves as a notification of these categories being addressed. The company, formerly known as Edge Therapeutics, Inc., is incorporated in Delaware and headquartered in Princeton, NJ.
Why It Matters
This 8-K filing indicates that PDS Biotechnology Corporation is providing updates or disclosures related to its financial statements and other significant events, which could be material to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K notification and does not contain specific negative or positive news, making the immediate risk level low.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- Edge Therapeutics, Inc. (company) — Former company name
- May 9, 2024 (date) — Date of earliest event reported
- Princeton, NJ (location) — Principal Executive Offices
FAQ
What specific "Other Events" are being reported by PDS Biotechnology Corporation in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the "Other Events"; it only lists the item information category.
Are there any new financial statements or exhibits included with this 8-K filing?
The filing indicates "Financial Statements and Exhibits" as an item information category, but the specific content of these is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 9, 2024.
What was PDS Biotechnology Corporation's former company name?
PDS Biotechnology Corporation's former company name was Edge Therapeutics, Inc.
Where are PDS Biotechnology Corporation's principal executive offices located?
PDS Biotechnology Corporation's principal executive offices are located at 303A College Road East, Princeton, NJ 08540.
Filing Stats: 461 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-05-09 19:38:46
Key Financial Figures
- $0.00033 — h registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20028859_8k.htm (8-K) — 28KB
- ef20028859_ex99-1.htm (EX-99.1) — 24KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-025256.txt ( ) — 195KB
- pdsb-20240509.xsd (EX-101.SCH) — 4KB
- pdsb-20240509_lab.xml (EX-101.LAB) — 21KB
- pdsb-20240509_pre.xml (EX-101.PRE) — 16KB
- ef20028859_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On May 9, 2024, PDS Biotechnology Corporation issued a press release announcing it hosted a Key Opinion Leader event on May 8, 2024 during which prominent experts in head and neck squamous cell cancer ("HNSCC") discussed positive, updated VERSATILE-002 data and the unmet need in HPV-positive HNSCC. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated May 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: May 9, 2024 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer